Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05804227
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05799612
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Multi-site Feasibility and Acceptability of a Faith-based Mind-body Intervention for Black Adults
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT05791981
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Post-Transplant Maintenance Therapy with Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT05776979
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trial of PreoperAtive Radiation (TOPAz): a Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy with Immediate Autologous Breast Reconstruction with Integrated Nanomechanical Biomarker Evaluation
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 126
- Registration Number
- NCT05774678
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT05773040
- Locations
- 🇺🇸
The University of Texas M D Anderson Cancer Center, Houston, Texas, United States
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 225
- Registration Number
- NCT05766891
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Developing a Culturally Relevant Supportive Care Program for Black Patients Dealing With Advanced Cancer
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05763797
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Smartphone-delivered Scheduled Smoking With Compliance Facilitation as an Adjunct Cessation Therapy: a Feasibility Study
Not Applicable
Recruiting
- Conditions
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT05763771
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05761951
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath